Rocket Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-223.1M | $-258.7M | $-245.6M | $-221.9M | $-169.1M | $-139.7M | $-77.3M | $-74.5M |
| Depreciation & Amortization | $8.9M | $7.2M | $4.9M | $3.9M | $3.2M | $1.1M | $426.0K | $330.0K |
| Depreciation | — | — | — | — | — | — | $426.0K | $330.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $37.1M | $43.9M | $39.4M | $31.0M | $29.2M | $18.6M | $13.4M | $13.6M |
| Net Cash from Operating Activities | $-190.0M | $-209.7M | $-194.9M | $-178.1M | $-121.2M | $-74.6M | $-64.7M | $-53.8M |
| Investing Activities | ||||||||
| Capital Expenditures | $440.0K | $5.9M | $16.4M | $8.4M | $7.6M | $20.6M | $23.3M | $1.5M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $103.8M | $131.7M | $-98.1M | $-69.3M | $18.9M | $-96.6M | $-39.0M | $-5.3M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | $0 | $72.0K | $0 | $0 |
| Net Cash from Financing Activities | $148.0K | $185.7M | $208.4M | $155.3M | $37.7M | $283.0M | $177.8M | $153.5M |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | $-190.5M | $-215.6M | $-211.4M | $-186.5M | $-128.8M | $-95.2M | $-87.9M | $-55.2M |